Edwards Lifesciences Corp EW
We take great care to ensure that the data presented and summarized in this overview for Edwards Lifesciences Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EW
View all-
Vanguard Group Inc Valley Forge, PA69.2MShares$5.34 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY51MShares$3.93 Billion0.11% of portfolio
-
Wellington Management Group LLP Boston, MA29.1MShares$2.25 Billion0.42% of portfolio
-
State Street Corp Boston, MA25.8MShares$1.99 Billion0.08% of portfolio
-
Jpmorgan Chase & CO New York, NY22MShares$1.7 Billion0.12% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il13.4MShares$1.03 Billion0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA12.7MShares$979 Million0.07% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa10.1MShares$780 Million0.32% of portfolio
-
Jennison Associates LLC10.1MShares$779 Million0.52% of portfolio
-
Brown Advisory Inc8.17MShares$631 Million0.89% of portfolio
Latest Institutional Activity in EW
Top Purchases
Top Sells
About EW
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Insider Transactions at EW
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 11
2025
|
Annette Bruls CVP, EMEACLA |
SELL
Payment of exercise price or tax liability
|
Direct |
109
-0.76%
|
$8,502
$78.8 P/Share
|
Jul 07
2025
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
333
-1.26%
|
$25,308
$76.79 P/Share
|
Jun 16
2025
|
Larry L Wood Global President TAVR & Surg |
SELL
Open market or private sale
|
Direct |
8,950
-4.15%
|
$671,250
$75.23 P/Share
|
Jun 16
2025
|
Larry L Wood Global President TAVR & Surg |
BUY
Exercise of conversion of derivative security
|
Direct |
8,950
+3.98%
|
$528,050
$59.26 P/Share
|
Jun 03
2025
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Indirect |
967
-10.11%
|
$74,459
$77.32 P/Share
|
Jun 02
2025
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
2,570
-4.86%
|
$197,890
$77.4 P/Share
|
May 30
2025
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Indirect |
16,099
-62.73%
|
$1,239,623
$77.21 P/Share
|
May 22
2025
|
Daveen Chopra CVP, TMTT |
SELL
Open market or private sale
|
Direct |
1,500
-4.29%
|
$112,500
$75.08 P/Share
|
May 16
2025
|
Bernard J Zovighian CEO |
BUY
Bona fide gift
|
Indirect |
5,815
+18.47%
|
-
|
May 16
2025
|
Bernard J Zovighian CEO |
SELL
Bona fide gift
|
Direct |
5,815
-6.7%
|
-
|
May 13
2025
|
Bernard J Zovighian CEO |
BUY
Bona fide gift
|
Indirect |
2,771
+12.25%
|
-
|
May 13
2025
|
Bernard J Zovighian CEO |
SELL
Bona fide gift
|
Direct |
2,771
-3.09%
|
-
|
May 11
2025
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,860
-3.09%
|
$208,780
$73.68 P/Share
|
May 11
2025
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
988
-0.48%
|
$72,124
$73.68 P/Share
|
May 11
2025
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,200
-2.92%
|
$87,600
$73.68 P/Share
|
May 11
2025
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-1.02%
|
$19,783
$73.68 P/Share
|
May 11
2025
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
580
-1.63%
|
$42,340
$73.68 P/Share
|
May 11
2025
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
816
-1.52%
|
$59,568
$73.68 P/Share
|
May 09
2025
|
Leslie C. Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,528
+34.89%
|
-
|
May 09
2025
|
David T Feinberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,528
+37.68%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 149K shares |
---|---|
Exercise of conversion of derivative security | 152K shares |
Bona fide gift | 16.5K shares |
Open market or private sale | 199K shares |
---|---|
Payment of exercise price or tax liability | 28.1K shares |
Bona fide gift | 16.5K shares |